DE112010003084T5 - Fulvestrant in einer Dosierung von 500 mg zur Behandlung von fortgeschrittenem Brustkrebs - Google Patents
Fulvestrant in einer Dosierung von 500 mg zur Behandlung von fortgeschrittenem Brustkrebs Download PDFInfo
- Publication number
- DE112010003084T5 DE112010003084T5 DE112010003084T DE112010003084T DE112010003084T5 DE 112010003084 T5 DE112010003084 T5 DE 112010003084T5 DE 112010003084 T DE112010003084 T DE 112010003084T DE 112010003084 T DE112010003084 T DE 112010003084T DE 112010003084 T5 DE112010003084 T5 DE 112010003084T5
- Authority
- DE
- Germany
- Prior art keywords
- fulvestrant
- patients
- treatment
- progression
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0912999.0 | 2009-07-27 | ||
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
| PCT/GB2010/051228 WO2011012885A1 (en) | 2009-07-27 | 2010-07-26 | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE112010003084T5 true DE112010003084T5 (de) | 2012-09-06 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE112010003084T Withdrawn DE112010003084T5 (de) | 2009-07-27 | 2010-07-26 | Fulvestrant in einer Dosierung von 500 mg zur Behandlung von fortgeschrittenem Brustkrebs |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| MA40271A (fr) * | 2014-05-21 | 2017-03-29 | Hoffmann La Roche | Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| WO2018075071A1 (en) * | 2016-10-21 | 2018-04-26 | Wade Hull | Pharmaceutical compositions |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 FI FI20125207A patent/FI20125207A7/fi not_active Application Discontinuation
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
Non-Patent Citations (26)
| Title |
|---|
| Addo S, Yates RA, Laight A. A Phase I trial to assess the pharmacology of the new oestrogen receptor antagonist Fulvestrant an the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87:1354-9 |
| Beatson 1896 |
| Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma; suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104-7 |
| Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. A double blind, randomized Placebo controlled trial of fulvestrant versus exemestane following prior nonsteroidal aromatase inhibitor therapy in post-menopausal women with hormone receptor positive advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664-70 |
| Collet D. Modelling Survival Data in Medical Research. Chapman and Hall, 1997 |
| Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M. Rubinstein L et al. Recommendations for the assessment of progression in randomised cancer treatment trials. European Journal of Cancer 2009; 45:281-289 |
| DeFriend DJ, Howell A, Nicholson RI, Anderson B, Dowsett M. Mansel RE, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994; 54:408-414 |
| Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008; 26:3791-6 |
| Ellis S, Carroll KJ, Pemberton K. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65 |
| Fisher B, Anderson S, Tan-Chiu F, Wolmark N, Wicherham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer findings from the National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001; 19(4):931-42 |
| Fisher et al 2001 |
| Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (FASLODEX): development of a novel, "pure" anti-estrogen. Cancer 2000; 89:817-25 |
| Howell A, Pippen J, Elledge RM, Mauriac L, Vergote 1, Jones SE, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236-239 |
| Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol, 2002; 20: 3396-3403 |
| Howell et al 2000, Robertson et al 2001, Wakeling et al 1991 |
| Howell et al 2002, Osborne et al 2002, Chia et al 2008 |
| Mcpherson et al 2000 |
| McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer - epidemiology, risk factors and genetics. BMJ 2000; 321:624-8. |
| Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol, 2002; 20: 3386-3395 |
| Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z. Dowsett M. et al,. Comparison of the store-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (FASLODEX) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 6:6739-46 |
| Robertson JFR, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. A prospective combined analysis of two multicenter trials. Cancer 2003; 98(2):229-38 |
| The NCCN Clinical Practice Guidelines in OncologyTM Breast Cancer (Version 1.2009)(CR) Available at: NCCN. org. Accessed [June 22, 2009]. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN. org. |
| Wakeling AE, Dukes M, Bowler J. A potent specific pure anti-estrogen with clinical potential. Cancer Research 1991; 51:3867-73 |
| Weibe VJ, Osborne CK, Fuqua SAW, DE, Gregoria MW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993:14:173-88 |
| Whitehead J. The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med 1989; 8(12):1439-54 |
| Wiebe et al 1993 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60118430T2 (de) | Behandlung von gastrointestinalen stromatumoren | |
| Klaiber et al. | Estrogen therapy for severe persistent depressions in women | |
| DE112010003084T5 (de) | Fulvestrant in einer Dosierung von 500 mg zur Behandlung von fortgeschrittenem Brustkrebs | |
| DE102007011486A1 (de) | Arzneimittel umfassend wenigstens ein Gestagen | |
| DE69231955T2 (de) | Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz | |
| DE102009007771A1 (de) | Bukkales Applikationssystem, 17α-Estradiol enthaltend | |
| DE69736644T2 (de) | Verfahren zur Vorbeugung von Brustkrebs durch Verabreichung von Raloxifen | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| DE60113975T2 (de) | Verwendung von fulvestrant in der behandlung von resistentem brustkrebs | |
| DE60121980T2 (de) | Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom | |
| EP1091744A1 (de) | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholin (et180ch3) zur behandlung von humanen mammakarzinomen | |
| DE69430356T2 (de) | Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält | |
| EP3166614B1 (de) | Zusammensetzung zur prävention und therapie von tumorerkrankungen | |
| DE60112750T2 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
| DE69730045T2 (de) | Behandlung der harninkontinenz und zusammenstellung dafür | |
| DE3240044A1 (de) | Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs | |
| AU2012100098A4 (en) | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer | |
| DE19908762A1 (de) | Verwendung von Dienogest in hoher Dosierung | |
| Schreml | 10 Jahre Therapie des Mammakarzinoms | |
| EP0495825B1 (de) | Verwendung von antigestagenen zur herstellung von arzneimitteln | |
| Groth et al. | Impact of transdermal estrogens treatment on postmenopausal symptoms and health-related quality of life: an Italian multicenter trial | |
| KR20210019402A (ko) | 주사용 조성물 | |
| Yacoub | Reduction of diameter of hair shaft among women with hirsutism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R163 | Identified publications notified | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20150203 |